* FTSE 100 up 0.1%, FTSE 250 up 0.2%
* Aviva steepest decliner on main board
* Pound gains on election hopes
* IQE tanks after results warning
* Buyout offer spurs Consort Medical (Adds news items, updates to closing prices)
By Muvija M and Shashwat Awasthi
Nov 18 (Reuters) - UK mid-caps closed at their highest level in nearly 14 months on Monday, boosted by polls pointing to victory by the ruling Conservatives in upcoming elections, while a near 5% drop in insurer Aviva weighed on the main board.
A win by the opposition Labour Party "could cause turmoil on the markets given the party wants to renationalise several sectors and shake up taxes," Russ Mould, investment director at AJ Bell, said.
"However, a lot can change in politics in three weeks so the markets are likely to remain volatile right up to the big vote."
The bluechips ended higher after their worst weekly performance in four despite a fall in oil majors, as investors pooled their money into the so-called defensive stocks that are perceived less risky at times of uncertainties.
Contradictory reports on Washington and Beijing's trade dispute kept the market on edge. Chinese news agency Xinhua said China and the United States had had "constructive talks", while CNBC reported that U.S. President Donald Trump was reluctant to roll back tariffs. from healthcare giant AstraZeneca AZN.L to consumer goods company Reckitt Benckiser RB.L gained, despite rises in the pound.
Aviva AV.L fell 4.6% to its lowest point since October after the insurer said it would keep its operations in Singapore and China amid speculation of a sale of the Singapore business.
"The fact that they have not been able to get a bid for it or come to an agreement to sell it would lead you to believe that they were unable to sell it so it isn't worth what they think it is," a trader said.
Among smaller companies, IQE IQE.L plunged 23% after the tech firm warned on results amid issues with two of its main customers. Consort Medical CSRT.L sky-rocketed 44% past the 10.1 pound a share level on a bid from Sweden's Recipharm RECIb.ST . firm Puretech PRTC.L jumped 14% to top the FTSE 250 index after its affiliate Karuna Therapeutics said its experimental treatment for acute psychosis in schizophrenia met key goals in a mid-stage trial.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.